2 - DNA Methylation and Cancer

https://doi.org/10.1016/B978-0-12-380866-0.60002-2Get rights and content

Abstract

DNA methylation is one of the most intensely studied epigenetic modifications in mammals. In normal cells, it assures the proper regulation of gene expression and stable gene silencing. DNA methylation is associated with histone modifications and the interplay of these epigenetic modifications is crucial to regulate the functioning of the genome by changing chromatin architecture. The covalent addition of a methyl group occurs generally in cytosine within CpG dinucleotides which are concentrated in large clusters called CpG islands. DNA methyltransferases are responsible for establishing and maintenance of methylation pattern. It is commonly known that inactivation of certain tumor-suppressor genes occurs as a consequence of hypermethylation within the promoter regions and a numerous studies have demonstrated a broad range of genes silenced by DNA methylation in different cancer types. On the other hand, global hypomethylation, inducing genomic instability, also contributes to cell transformation. Apart from DNA methylation alterations in promoter regions and repetitive DNA sequences, this phenomenon is associated also with regulation of expression of noncoding RNAs such as microRNAs that may play role in tumor suppression. DNA methylation seems to be promising in putative translational use in patients and hypermethylated promoters may serve as biomarkers. Moreover, unlike genetic alterations, DNA methylation is reversible what makes it extremely interesting for therapy approaches. The importance of DNA methylation alterations in tumorigenesis encourages us to decode the human epigenome. Different DNA methylome mapping techniques are indispensable to realize this project in the future.

Introduction

To establish an organism, classical genetic processes are not sufficient. For proper development and cell functioning, the epigenetic phenomena are absolutely required, controlling gene expression. Epigenetic could be defined as study of heritable changes in gene expression that occur independently of changes in primary DNA sequence. Distinct epigenomes may explain differences in cell state during development when zygote transforms to somatic tissue, even if the DNA stays the same. It seems also logic that epigenetic correlates with several diseases, that has been proved in monozygotic twins that are sharing exactly the same genetic material but not necessarily the same epigenome (Fraga et al., 2005).

Epigenetic regulation of gene expression is mediated by mechanisms such as methylation of DNA, modifications of histones, and positioning of nucleosome along the DNA. The interplay between epigenetic components guarantees proper balance between transcriptional activity and repression by changing chromatin architecture. Thus, regulation of packaging of DNA ensures maintenance of correct chromosome replication, gene expression, and stable gene silencing (Esteller, 2007). DNA methylation is one of the most intensely studied epigenetic modifications in mammals and it has an important impact on normal cell physiology. As this DNA modification seems to be a critical player in the transcriptional regulation, it is not surprising that defects in this mechanism may lead to various diseases, including cancer (Esteller, 2008). Indeed, in 1983 Feinberg and Vogelstein observed reduction of DNA methylation of specific genes in human colon cancer cells, comparing with normal tissues (Feinberg and Vogelstein, 1983). In the same year, Gama-Sosa et al. described a global reduction of 5-methylcytosine content of DNA from tumor samples (Gama-Sosa et al., 1983). Since these findings, being the first proof of molecular epigenetic abnormalities in cancer, we have significantly broadened our knowledge in that field (Esteller, 2008). Even if there is still far less known about epigenetic inheritance system and mechanisms of action than traditional genetics, the importance of DNA methylation in carcinogenesis is beyond any doubt.

In this chapter, we will try to summarize our actual state of knowledge concerning DNA methylation alteration in tumor progression.

Section snippets

The Molecular Basis of DNA Methylation

The propagation of DNA methylation is well understood at the biochemical level. It consists of the covalent addition of a methyl group (–CH3) that occurs exclusively at the 5 position of the cytosine moiety (Fig. 2.1A). Intriguingly, methylated cytosine could be converted into 5-hydroxymethylcytosine (hmC), structurally similar to its unmodified counterpart (Tahiliani et al., 2009). This kind of modification was found in cerebellar Purkinje neurons and in embryonic stem cells but the biological

DNA Methylation Abnormalities in Cancer

Appropriate DNA methylation is essential for development and proper cell functioning, thus any abnormalities in this process may lead to various diseases, including cancer. Indeed, tumor cells are characterized by a different methylome from that of normal cells. Interestingly, both hypo- and hypermethylation events can be observed in cancer. Generally, a global decrease in methylated CpG content is observed. This phenomenon contributes to genomic instability and, less frequently, to activation

DNA Methylation Markers

Despite our constantly growing understanding of carcinogenesis, there is still an eager needs to design novel, powerful tools that can be applied as part of clinical practice. Tumor biomarkers are indispensable not only for early diagnosis of cancer but also for prognosis, prediction of therapeutic response, monitoring therapy, or assessment of risk of recurrence after curative surgery. Many different molecules, including nucleic acids, proteins, or even small metabolites, could be used as the

Determining the Cancer DNA Methylome

The importance of DNA methylation alterations in tumorigenesis encourages us to decode the human epigenome. Nowadays, various methods are available to assess the DNA methylation pattern of particular DNA regions. Important progress has also been made toward completing a large-scale analysis of DNA methylation.

5-Methylcytosines can be detected by three possible methods based on (1) bisulfite conversion of DNA, (2) methyl-sensitive restriction enzymes, or (3) chromatin immunoprecipitation (ChIP)

Therapy Perspectives

Unlike genetic alterations, epigenetic events, including DNA methylation, are reversible, which makes it extremely interesting from the point of view of developing new approaches to therapy. The agents capable of restoring the normal cell DNA methylation pattern have been developed in the course of several studies. The strategies use special drugs to inactivate DNMTs. As an expected result of this approach, DNMT inhibitors should trigger the loss of the overall level that is thought to randomly

Conclusions

Since its discovery, DNA methylation has captured a lot of interest and its fundamental role in proper cell functioning is broadly recognized. Numerous studies have shown the key role of DNA methylation in tumor development and progression. Particularly, promoter hypermethylation resulting in gene silencing is one of the central players in cancer. In addition to classical genetic abnormalities, DNA methylation aberrations are considered as a second layer of tumorigenesis complexicity. Moreover,

References (118)

  • E. Li et al.

    Targeted mutation of the DNA methyltransferase gene results in embryonic lethality

    Cell

    (1992)
  • R.K. Lin et al.

    Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer

    Lung Cancer

    (2007)
  • S. Mulero-Navarro et al.

    Epigenetic biomarkers for human cancer: The time is now

    Crit. Rev. Oncol. Hematol.

    (2008)
  • M. Okano et al.

    DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development

    Cell

    (1999)
  • V.R. Ramirez-Carrozzi et al.

    A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling

    Cell

    (2009)
  • C. Rodriguez et al.

    CTCF is a DNA methylation-sensitive positive regulator of the INK/ARF locus

    Biochem. Biophys. Res. Commun.

    (2010)
  • L.J. Rush et al.

    Restriction landmark genomic scanning for DNA methylation in cancer: Past, present, and future applications

    Anal. Biochem.

    (2002)
  • Y. Saito et al.

    Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells

    Cancer Cell

    (2006)
  • G. Sharma et al.

    CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients

    Clin. Biochem.

    (2010)
  • J.A. Simon et al.

    Roles of the EZH2 histone methyltransferase in cancer epigenetics

    Mutat. Res.

    (2008)
  • Y. Akiyama et al.

    GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer

    Mol. Cell. Biol.

    (2003)
  • V. Badal et al.

    CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: Genomic hypomethylation correlates with carcinogenic progression

    J. Virol.

    (2003)
  • E.K. Baker et al.

    Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs

    Oncogene

    (2005)
  • E. Ballestar et al.

    Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer

    EMBO J.

    (2003)
  • G.J. Brock et al.

    A novel technique for the identification of CpG islands exhibiting altered methylation patterns (ICEAMP)

    Nucleic Acids Res.

    (2001)
  • B. Brueckner et al.

    Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases

    Cancer Res.

    (2005)
  • O.L. Caballero et al.

    Cancer/testis (CT) antigens: Potential targets for immunotherapy

    Cancer Sci.

    (2009)
  • D. Carlow et al.

    Substrate connectivity effects in the transition state for cytidine deaminase

    Biochemistry

    (1998)
  • F. Chedin et al.

    The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a

    Proc. Natl. Acad. Sci. USA

    (2002)
  • W.D. Chen et al.

    Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene

    J. Natl. Cancer Inst.

    (2005)
  • L. Chin et al.

    Translating insights from the cancer genome into clinical practice

    Nature

    (2008)
  • J.K. Christman

    5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy

    Oncogene

    (2002)
  • J.M. Daniel et al.

    The p120(ctn)-binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides

    Nucleic Acids Res.

    (2002)
  • J. Datta et al.

    A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation

    Cancer Res.

    (2009)
  • V. Davalos et al.

    MicroRNAs and cancer epigenetics: A macrorevolution

    Curr. Opin. Oncol.

    (2010)
  • C. Deng et al.

    Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling

    Arthritis Rheum.

    (2003)
  • R. Deplus et al.

    Dnmt3L is a transcriptional repressor that recruits histone deacetylase

    Nucleic Acids Res.

    (2002)
  • O.Y. Dokun et al.

    Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer

    Int. J. Cancer

    (2008)
  • H.G. Drexler

    Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells

    Leukemia

    (1998)
  • C.A. Eads et al.

    MethyLight: A high-throughput assay to measure DNA methylation

    Nucleic Acids Res.

    (2000)
  • M. Esteller

    The necessity of a human epigenome project

    Carcinogenesis

    (2006)
  • M. Esteller

    Cancer epigenomics: DNA methylomes and histone-modification maps

    Nat. Rev. Genet.

    (2007)
  • M. Esteller

    Epigenetics in cancer

    N. Engl. J. Med.

    (2008)
  • M. Esteller et al.

    Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

    Cancer Res.

    (1999)
  • M. Esteller et al.

    Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer

    Cancer Res.

    (2002)
  • A.P. Feinberg et al.

    Hypomethylation distinguishes genes of some human cancers from their normal counterparts

    Nature

    (1983)
  • A.P. Feinberg et al.

    The epigenetic progenitor origin of human cancer

    Nat. Rev. Genet.

    (2006)
  • G.J. Filion et al.

    A family of human zinc finger proteins that bind methylated DNA and repress transcription

    Mol. Cell. Biol.

    (2006)
  • A.S. Fleisher et al.

    Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia

    Oncogene

    (2001)
  • M.F. Fraga et al.

    Epigenetic differences arise during the lifetime of monozygotic twins

    Proc. Natl. Acad. Sci. USA

    (2005)
  • Cited by (1181)

    View all citing articles on Scopus
    View full text